European Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union

Impact · against what's priced in

ACAD receives a significant fundamental catalyst as DAYBU becomes the first and only approved treatment for Rett syndrome in the EU. This grants the company immediate first-mover advantage and opens a massive new geographic revenue stream.

ACAD+0.80

No priced-in read yet